Eli Lilly and CoXSWX:LLY -2.03%100 5-Year Yield-on-Cost % is 1.06 as of Jul. 12, 2026, which is 63% below its 10-year median of 2.84. GuruFocus rates XSWX:LLY with a GF Score™ of 100/100 and a GF Value™ of CHF1,131.77 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 516 Drug Manufacturers companies, Eli Lilly and Co ranks worse than 69.96% on this metric.
Eli Lilly and Co's yield on cost for the quarter that ended in Mar. 2026 was 1.06.
The historical rank and industry rank for Eli Lilly and Co's 5-Year Yield-on-Cost % or its related term are showing as below:
XSWX:LLY'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.03 Med: 2.84 Max: 6.09
Current: 1.06
During the past 13 years, Eli Lilly and Co's highest Yield on Cost was 6.09. The lowest was 1.03. And the median was 2.84.
XSWX:LLY's 5-Year Yield-on-Cost % is ranked worse than 69.96% of 516
companies
in the Drug Manufacturers industry
Industry Median: 2.205
vs XSWX:LLY: 1.06
Eli Lilly and Co (XSWX:LLY) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Eli Lilly and Co 5-Year Yield-on-Cost % Related Terms
XSWX:LLY vs JNJ, ABBV, MRK: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - General subindustry, Eli Lilly and Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eli Lilly and Co 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Eli Lilly and Co's 5-Year Yield-on-Cost % falls into.
Eli Lilly and Co 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Eli Lilly and Co (XSWX:LLY) has a 5-Year Yield-on-Cost % of 1.06 as of Jul. 12, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Eli Lilly and Co and its competitors. This is 63% below median its historical median of 2.84. Over the past decade, Eli Lilly and Co's 5-Year Yield-on-Cost % has ranged from 1.03 to 6.09. According to the industry distribution chart, Eli Lilly and Co ranks #361 out of 516 companies in the Drug Manufacturers industry, placing it in the top 70%.
Is Eli Lilly and Co's 5-Year Yield-on-Cost % too high?
Eli Lilly and Co's current 5-Year Yield-on-Cost % of 1.06 is 63% below median its 10-year median of 2.84. Over the past 10 years, this metric has ranged from a low of 1.03 to a high of 6.09. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.21. Eli Lilly and Co's value of 1.06 is 51.9% below this industry median. Based on the distribution chart, Eli Lilly and Co ranks #361 out of 516 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Eli Lilly and Co has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's 5-Year Yield-on-Cost % compare to JNJ and ABBV?
According to the Drug Manufacturers industry distribution chart, Eli Lilly and Co ranks #361 out of 516 companies for 5-Year Yield-on-Cost %. This places Eli Lilly and Co in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.21. Eli Lilly and Co's value of 1.06 is 51.9% below this benchmark. Historically, Eli Lilly and Co's own 5-Year Yield-on-Cost % has ranged from 1.03 to 6.09 over the past decade. While the company's 10-year median is 2.84 vs. the industry median of 2.21, Eli Lilly and Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.21, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eli Lilly and Co's current 5-Year Yield-on-Cost % of 1.06 is 51.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Eli Lilly and Co and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eli Lilly and Co's current 5-Year Yield-on-Cost % is 1.06, which is 63% below median its own 10-year median of 2.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (XSWX:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF1,131.77, compared to a current price of CHF965.00 — trading 14.7% below its estimated fair value. The current 5-Year Yield-on-Cost % is 1.06, which is 63% below median its 10-year median of 2.84 and 51.9% below the Drug Manufacturers industry median of 2.21. Eli Lilly and Co's overall GF Score™ is 100/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Eli Lilly and Co (XSWX:LLY), the current 5-Year Yield-on-Cost % is 1.06 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eli Lilly and Co (XSWX:LLY) Overvalued in 2026?
Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued.
The current stock price of CHF965.00 is trading 14.7% below its estimated GF Value™ of CHF1,131.77.
GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.
Key valuation signals for XSWX:LLY:
5-Year Yield-on-Cost %: 1.06 (63% below median its 10-year median of 2.84)
GF Value™: CHF1,131.77 vs. price of CHF965.00 (14.7% below fair value)
Industry Position: 51.9% below the Drug Manufacturers median (#361 of 516)
No single metric tells the full story. See the XSWX:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
100GF Score
Get the complete analysis for XSWX:LLY
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:LLY has been successfully added to your 